stockrow
Friday 6 November 2026
Export RXRX’s income statement to Excel — free account
Recursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.
- Revenue
- +258.5%
- EPS
- +39.1%
- Free cash flow
- +33.8%
- Total debt
- −99.2%
Quarter to September 2026, against a year earlier
3.52
0.02
+0.57%
Follow RXRX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 5 | 3 |
+8 more TTM periods Free account |
| (48.72%) | (56.58%) | (57.16%) | (59.54%) | ||
| (36.29%) | (41.26%) | (42.33%) | (44.12%) | ||
ROIC |
(88.54%) | (92.22%) | (98.34%) | (103.19%) | |
Return on Tangible Assets |
(82.16%) | (90.52%) | (82.85%) | (83.84%) | |
Average Days of Receivables |
182.23 | 95.77 | 74.67 | 120.47 | |
Free Cash Flow per Share |
(0.58) | (0.67) | (0.62) | (0.85) | |
Free Cash Flow |
(314.47) | (354.26) | (328.08) | (380.43) | |
Capital Expenditures |
(3.95) | (3.78) | (7.13) | (8.63) | |
| Other line items | |||||
Cash ROIC |
(21.50%) | (24.09%) | (19.39%) | (20.15%) | |
Accounts Receivable Turnover |
2.44 | 3.05 | 2.22 | 2.02 | |
Accounts Payable Turnover |
3.19 | 3.31 | 2.71 | 3.57 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
123.81 | 87.36 | 120.54 | 93.20 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
(0.01) | (0.01) | (0.01) | 0.00 | |
Research and Development Expense of Revenue |
546.04% | 719.19% | 652.83% | 636.40% | |
Selling, General and Administrative Expense of Revenue |
208.62% | 276.02% | 235.71% | 236.46% | |
Share Based Compensation of Revenue |
129.71% | 165.38% | 146.64% | 148.93% | |
Operating CF/Net income |
0.65 | 0.68 | 0.57 | 0.58 | |
Depreciation/Fixed assets |
0.86 | 0.87 | 0.88 | 0.81 | |
Capex/Depreciation |
(0.05) | (0.05) | (0.08) | (0.10) | |
Revenue per Share |
0.13 | 0.10 | 0.13 | 0.17 | |
Operating CF per Share |
(0.57) | (0.66) | (0.61) | (0.83) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.06 | 0.07 | 0.11 | 0.12 |
Columns are period end dates · fundamentals updated 5 Nov 2026